Bayesian methods in clinical trials with applications to medical devices

다국어 초록 (Multilingual Abstract)

Bayesian statistics can play a key role in the design and analysis of clinical trials and this has been demonstrated for medical device trials. By 1995 Bayesian statistics had been well developed and the revolution in computing powers and Markov chain Monte Carlo development made calculation of posterior distributions within computational reach. The Food and Drug Administration (FDA) initiative of Bayesian statistics in medical device clinical trials, which began almost 20 years ago, is reviewed in detail along with some of the key decisions that were made along the way. Both Bayesian hierarchical modeling using data from previous studies and Bayesian adaptive designs, usually with a non-informative prior, are discussed. The leveraging of prior study data has been accomplished through Bayesian hierarchical modeling. An enormous advantage of Bayesian adaptive designs is achieved when it is accompanied by modeling of the primary endpoint to produce the predictive posterior distribution. Simulations are crucial to providing the operating characteristics of the Bayesian design, especially for a complex adaptive design. The 2010 FDA Bayesian guidance for medical device trials addressed both approaches as well as exchangeability, Type I error, and sample size. Treatment response adaptive randomization using the famous extracorporeal membrane oxygenation example is discussed. An interesting real example of a Bayesian analysis using a failed trial with an interesting subgroup as prior information is presented. The implications of the likelihood principle are considered. A recent exciting area using Bayesian hierarchical modeling has been the pediatric extrapolation using adult data in clinical trials. Historical control information from previous trials is an underused area that lends itself easily to Bayesian methods. The future including recent trends, decision theoretic trials, Bayesian benefit-risk, virtual patients, and the appalling lack of penetration of Bayesian clinical trials in the medical literature are discussed.

참고문헌 (Reference)

1 Spiegelhalter D, "WinBUGS version 1.4.1 user manual"

2 Berry DA, "Using a Bayesian approach in medical device development"

3 Viele K, "Use of historical control data for assessing treatment effects in clinical trials" 13 : 41-54, 2014

4 Fayers PM, "Tutorial in biostatistics Bayesian data monitoring in clinical trials" 16 : 1413-1430, 1997

5 Goodman SN, "Toward evidence-based medical statistics, II : the Bayes factor" 130 : 1005-1013, 1999

6 Goodman SN, "Toward evidence-based medical statistics, I : the P value fallacy" 130 : 995-1004, 1999

7 Freedman LS, "The what, why and how of Bayesian clinical trials monitoring monitoring" 13 : 1371-1383, 1994

8 Saville BR, "The utility of Bayesian predictive probabilities for interim monitoring of clinical trials" 11 : 485-493, 2014

9 Food and Drug Administration, "The use of Bayesian statistics in medical device clinical trials: guidance for industry and Food and Drug Administration staff"

10 Wei LJ, "The randomized play-the-winner rule in medical trials" 73 : 830-843, 1978

11 Campbell G, "The maximum of a sequence with prior information, Communications in Statistics" 1 : 177-191, 1982

12 Campbell G, "The experience in the FDA’s Center for Devices and Radiological Health with Bayesian strategies" 2 : 359-363, 2005

13 Hu F, "The Theory of Response-Adaptive Randomization in Clinical Trials" Wiley 2006

14 Berger JO, "The Likelihood Principle" Institute of Mathematical Statistics 1988

15 Parmar MKB, "The CHART trials : Bayesian design and monitoring in practice" 13 : 1297-1312, 1994

16 Wasserman RL, "The ASA’s statement on p-values : context, process and purpose" 70 : 129-133, 2016

17 Ashby D, "Stopping rules, interim analyses and data monitoring committees" 68 : 1047-1050, 1993

18 Geman S, "Stochastic relaxation, Gibbs distribution and Bayesian restoration of images" 6 : 721-741, 1984

19 Gamalo-Siebers M, "Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation" 16 : 232-249, 2017

20 Campbell G, "Statistical innovations in the medical device world sparked by the FDA" 26 : 3-16, 2016

21 Berger JO, "Statistical analysis and the illusion of objectivity" 76 : 159-165, 1988

22 Campbell G, "Similarities and differences of Bayesian designs and adaptive designs for medical devices : a regulatory view" 5 : 356-368, 2013

23 Sung L, "Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study" 58 : 261-268, 2005

24 Murray TA, "Semiparametric Bayesian commensurate survival model for post-market medical device surveillance with non-exchangeable historical data" 70 : 185-191, 2014

25 Inoue LYT, "Seamlessly expanding a randomized phase II trial to phase III" 58 : 823-831, 2002

26 Greenhouse JB, "Robust Bayesian methods for monitoring clinical trials" 14 : 1379-1391, 1995

27 Carlin BP, "Robust Bayesian approaches for clinical trial monitoring" 15 : 1093-1106, 1996

28 Hughes MD, "Reporting Bayesian analyses of clinical trials" 12 : 1651-1663, 1993

29 Campbell G, "Rank order estimation with the Dirichlet prior" 6 : 142-153, 1978

30 Kadane JB, "Prime time for Bayes" 16 : 313-318, 1995

31 Grieve AP, "Predictive probability in clinical trials" 47 : 323-330, 1991

32 Campbell G, "Prediction intervals with a Dirichlet-process prior distribution" 10 : 103-111, 1982

33 Ibrahim JG, "Power prior distributions for regression models" 15 : 46-60, 2000

34 Steven N. MacEachern, "Nonparametric Bayesian methods: a gentle introduction and overview" 한국통계학회 23 (23): 445-466, 2016

35 배레나, "Multiple Comparison for the One-Way ANOVA with the Power Prior" 한국통계학회 15 (15): 13-26, 2008

36 Food and Drug Administration, "Leveraging existing clinical data for extrapolation to pediatric uses of medical devices: guidance for Industry and Food and Drug Administration staff"

37 Ware JH, "Investigating therapies of potentially great benefit : ECMO (with discussion)" 4 : 298-340, 1989

38 Berry DA, "Introduction Bayesian methods III : uses and interpretation of Bayesian tools in design and analysis" 2 : 295-300, 2005

39 Louis TA, "Introduction Bayesian methods II : fundamental concepts" 2 : 291-294, 2005

40 Goodman SN, "Introduction Bayesian methods I : measuring the strength of evidence" 2 : 282-290, 2005

41 Berry DA, "Interim analysis in clinical trials : the role of the likelihood principle" 41 : 117-122, 1987

42 Haddad T, "Incorporation of stochastic engineering models as prior information in Bayesian medical device trials" 10 : 1-15, 2017

43 Temple R, "How FDA currently makes decisions on clinical studies" 2 : 276-281, 2005

44 Hobbs BP, "Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials" 67 : 1047-1056, 2011

45 Food and Drug Administration, "Guidance for industry: E9 statistical principles for clinical trials"

46 Lewis RJ, "Group sequential clinical trials: a classical evaluation of Bayesian decision-theoretic designs" 89 : 1528-1534, 1994

47 Chaloner K, "Graphical elicitation of a prior distribution for a clinical trial" 42 : 341-353, 1993

48 Food and Drug Administration, "FDA panel presentation for Therox P080005"

49 Woodcock J, "FDA introductory comments : clinical study design and evaluation issues" 2 : 273-275, 2005

50 Food and Drug Administration, "FDA CRADAs"

51 Pennello G, "Experience with reviewing Bayesian medical device trials" 18 : 81-115, 2007

52 Royall RM, "Ethics and statistics in randomized clinical trials(with discussion)" 6 : 52-88, 1991

53 Stone GW, "Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction" 2 : 366-375, 2009

54 Alderson NE, "Editorial" 2 : 271-272, 2005

55 Hobbs BP, "Commensurate priors for incorporating historical information in clinical trials using general and generalized linear models" 7 : 639-674, 2012

56 Muller P, "Clinical trial design as a decision problem" 33 : 296-301, 2017

57 Irony T, "Clinical Evaluation of Medical Devices, Principles and Case Studies" Humana Press 99-116, 2006

58 Cheng Y, "Choosing sample size for a clinical trial using decision analysis" 90 : 923-936, 2003

59 Dixon DO, "Bayesian subset analysis in a colorectal cancer clinical trial" 11 : 13-22, 1992

60 Simon R, "Bayesian subset analysis : application to studying treatment-by-gender interactions" 21 : 2909-2916, 2002

61 Ashby D, "Bayesian statistics in medicine : a 25 year review" 25 : 3589-3631, 2006

62 Campbell G, "Bayesian statistics in medical devices : innovation sparked by the FDA" 21 : 871-887, 2011

63 Berry DA, "Bayesian statistics and the efficiency and ethics of clinical trials" 19 : 175-187, 2004

64 Pibouleau L, "Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices" 64 : 270-279, 2011

65 Dmitrienko A, "Bayesian predictive approach to interim monitoring in clinical trials" 25 : 2178-2195, 2006

66 Lipscomb B, "Bayesian predictions of final outcomes : Regulatory approval of a spinal implant" 2 : 325-333, 2005

67 Chen MH, "Bayesian design of noninferiority trials for medical devices using historical data" 67 : 1163-1170, 2011

68 Gonen M, "Bayesian clinical trials : no more excuses" 6 : 203-204, 2009

69 Spiegelhalter DJ, "Bayesian approaches to randomised trials" 157 : 357-416, 1994

70 Bonangelino P, "Bayesian approaches in medical device clinical trials : a discussion with examples in the regulatory setting" 21 : 938-953, 2011

71 Gamalo MA, "Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products" 13 : 25-40, 2014

72 Ferguson TS, "Bayesian analysis of some nonparametric problems" 1 : 209-230, 1973

73 Chevret S, "Bayesian adaptive clinical trials : a dream for statisticians only?" 31 : 1002-1013, 2012

74 Campbell G, "Bayesian Statistics Applied to Pharmaceutical Research" CRC Press 2017

75 Carlin BP, "Bayesian Methods for Data Analysis" Chapman and Hall/CRC 2009

76 Kadane JB, "Bayesian Methods and Ethics in a Clinical Trial Design" Wiley 1996

77 Box GEP, "Bayesian Inference in Statistical Analysis" Addison-Wesley 1973

78 Gelman A, "Bayesian Data Analysis" Chapman & Hall/CRC 2013

79 Spiegelhalter DJ, "Bayesian Approaches to Clinical Trials and Health-Care Evaluation" Wiley 2004

80 Berry SM, "Bayesian Adaptive Methods for Clinical Trials" CRC Press 2011

81 Meurer WJ, "Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project" 17 : 373-, 2016

82 Parmar MKB, "Assessing whether to perform a confirmatory randomized clinical trial" 88 : 1645-1651, 1996

83 Freedman LS, "Application of Bayesian statistics to decision making during a clinical trial" 11 : 23-35, 1992

84 Meurer WJ, "An overview of the adaptive designs accelerating promising trials into treatments(ADAPT-IT)project" 60 : 451-457, 2012

85 Stokes M, "An introduction to Bayesian analysis with SAS/STAT software: paper SAS1775-2015"

86 Bayes, T, "An Essay Towards Solving a Problem in The Doctrine of Chances" 53 : 370-418, 1763

87 Pedroza C, "Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial : an example of a neonatal cooling trial" 17 : 335-, 2016

88 Food and Drug Administration, "Adaptive designs for medical device clinical studies: guidance for Industry and Food and Drug Administration staff"

89 Yang X, "Adaptive design practice at the Center for Devices and Radiological Health(CDRH), January 2007 to May 2013" 50 : 710-717, 2016

90 Hobbs BP, "Adaptive adjustment of the randomization ratio using historical control data" 10 : 430-440, 2013

91 Simon R, "A decade of progress in statistical methodology for clinical trials" 10 : 1789-1817, 1991

92 Malec D, "A closer look at combining data among a small number of binomial experiments" 20 : 1811-1824, 2001

93 Berry DA, "A case for Bayesianism in clinical trials" 12 : 1377-1393, 1993

94 Waddingham E, "A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment" 58 : 28-42, 2015

95 Grieve AP, "25 years of Bayesian methods in the pharmaceutical industry : a personal, statistical bummel" 6 : 261-281, 2007